632 HPN601 is a protease-activated EpCAM-targeting T cell engager with an improved safety profile for the treatment of solid tumors

by Richard Austin, Thomas Evans, Jack Lin, Sony Rocha, Kathryn Kwant, Maria Dayao, Tessie Ng, Wade Aaron, Evan Callihan, Maria Gamez-Guerrero, Golzar Hemmati, Kevin Wright, Manasi Barath, Yinghua Xiao, Master Degree, Timothy Yu, Patrick Chew, Jessica O’Rear, Scott Gatto, Michael Cremin, Stephen Yu, Purbasa Patnaik, Avneel Hundal, Bryan Lemon, Holger Wesche
Published 2020-11-01

Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer

by Adam R. Root, Wei Cao, Bilian Li, Peter LaPan, Caryl Meade, Jocelyn Sanford, Macy Jin, Cliona O’Sullivan, Emma Cummins, Matthew Lambert, Alfredo D. Sheehan, Weijun Ma, Scott Gatto, Kelvin Kerns, Khetemenee Lam, Aaron M. D’Antona, Lily Zhu, William A. Brady, Susan Benard, Amy King, Tao He, Lisa Racie, Maya Arai, Dianah Barrett, Wayne Stochaj, Edward R. LaVallie, James R. Apgar, Kristine Svenson, Lidia Mosyak, Yinhua Yang, Gurunadh R. Chichili, Liqin Liu, Hua Li, Steve Burke, Syd Johnson, Ralph Alderson, William J. J. Finlay, Laura Lin, Stéphane Olland, William Somers, Ezio Bonvini, Hans-Peter Gerber, Chad May, Paul A. Moore, Lioudmila Tchistiakova, Laird Bloom
Published 2016-03-01